Position Reflects Growing Importance of Business Partnerships
Biogen, Inc. (NASDAQ/BGEN) announced today that Christine Carberry has been appointed Vice President, Program and Alliance Management. Ms. Carberry will oversee Biogen’s development programs in the areas of autoimmune diseases, neurodegeneration, oncology and fibrosis. She also will be responsible for maintaining current and future business partnerships in these areas. She reports to John Palmer, Senior Vice President, Corporate Development.
Mr. Palmer said, “Biogen is on course to be a multi-product, multi-billion dollar company, and as the company moves forward, developing partnerships with businesses on novel therapeutic programs will play an even greater role in enhancing our already robust product pipeline. Christine brings skill in managing business alliances and more than 15 years of industry experience to this new position, and she will be instrumental in creating new opportunities for the company.”
Biogen has increased its emphasis on program development with partner companies over the last few years, most recently collaborating with Celltech Group plc on CDP 571, currently in Phase III trials for Crohn’s disease. Biogen is also collaborating with Elan Corporation, plc on ANTEGREN® (natalizumab), which is in Phase III trials for multiple sclerosis and Crohn’s disease, and with ICOS Corporation on LFA-1 (Leukocyte Function-associated Antigen-1), in Phase II trials for the treatment of immuno-inflammatory diseases, including psoriasis.
Ms. Carberry joined Biogen in 1984 and held many positions in Technical Operations, including managing the start-up of Biogen’s manufacturing facility in the Netherlands from 1999 to 2001. She was most recently the Program Executive of the LFA-1 program, which is developing orally active small molecule antagonists that work to inhibit T-cell migration and activation that can lead to inflammatory diseases.
Ms. Carberry holds a Master of Science in Innovation and Technology Management from Boston University and a Bachelor of Science in Biochemistry from the University of New Hampshire.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a biotechnology
company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from U.S. and European sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, (Please see full prescribing information at http://www.avonex.com.), and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s homepage on the World Wide Web at http://www.biogen.com.
Media Contact:
Amy Brockelman
Manager, Public Affairs
Biogen, Inc.
Tel: (617) 679-3860
Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen, Inc.
Tel: (617) 679-2521